Log in

NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News

$8.43
+0.16 (+1.93 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.88
Now: $8.43
$8.48
50-Day Range
$7.49
MA: $9.40
$11.41
52-Week Range
$4.53
Now: $8.43
$24.00
Volume307,898 shs
Average Volume415,916 shs
Market Capitalization$465.93 million
P/E RatioN/A
Dividend YieldN/A
Beta2.91
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Read More
Accelerate Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.30 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.30 million
Book Value($0.42) per share

Profitability

Net Income$-84,310,000.00
Net Margins-845.43%

Miscellaneous

Employees287
Market Cap$465.93 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

How has Accelerate Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AXDX shares have decreased by 20.5% and is now trading at $8.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Accelerate Diagnostics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Accelerate Diagnostics.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Accelerate Diagnostics.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) posted its earnings results on Thursday, May, 7th. The medical research company reported ($0.39) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.39). The medical research company earned $2.34 million during the quarter, compared to the consensus estimate of $2.40 million. Accelerate Diagnostics had a negative net margin of 845.43% and a negative return on equity of 5,681.44%. View Accelerate Diagnostics' earnings history.

What guidance has Accelerate Diagnostics issued on next quarter's earnings?

Accelerate Diagnostics issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.32 million.

What price target have analysts set for AXDX?

3 brokerages have issued 1 year price objectives for Accelerate Diagnostics' stock. Their forecasts range from $14.00 to $19.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $16.33 in the next year. This suggests a possible upside of 93.8% from the stock's current price. View analysts' price targets for Accelerate Diagnostics.

Has Accelerate Diagnostics been receiving favorable news coverage?

News stories about AXDX stock have been trending extremely negative on Sunday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Accelerate Diagnostics earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutAccelerate Diagnostics.

Are investors shorting Accelerate Diagnostics?

Accelerate Diagnostics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 16,640,000 shares, an increase of 5.4% from the April 30th total of 15,780,000 shares. Based on an average daily trading volume, of 447,000 shares, the short-interest ratio is currently 37.2 days. Currently, 52.9% of the company's shares are short sold. View Accelerate Diagnostics' Current Options Chain.

Who are some of Accelerate Diagnostics' key competitors?

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL).

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:
  • Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
  • Mr. Steve Reichling, Chief Financial Officer (Age 41)
  • Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
  • Mr. Kurt Reinhardt, Head of Operations
  • Dr. Romney M. Humphries, Chief Scientific Officer (Age 38)

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.64%), AXA (3.62%), Griffin Asset Management Inc. (2.52%), ArrowMark Colorado Holdings LLC (1.91%), Chicago Capital LLC (1.58%) and State Street Corp (1.09%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View institutional ownership trends for Accelerate Diagnostics.

Which major investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including CSS LLC IL, Chicago Capital LLC, Morgan Stanley, ArrowMark Colorado Holdings LLC, AXA, Parametric Portfolio Associates LLC, Blair William & Co. IL, and UBS Group AG. View insider buying and selling activity for Accelerate Diagnostics.

Which major investors are buying Accelerate Diagnostics stock?

AXDX stock was bought by a variety of institutional investors in the last quarter, including Griffin Asset Management Inc., BNP Paribas Arbitrage SA, Two Sigma Investments LP, Baird Financial Group Inc., Raging Capital Management LLC, Oxford Financial Group Ltd., Two Sigma Advisers LP, and State Street Corp. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling, and Thomas D Brown. View insider buying and selling activity for Accelerate Diagnostics.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $8.43.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $465.93 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.